公开(公告)号：US20070032429A1

公开(公告)日：2007-02-08

申请号：US11544507

申请日：2006-10-05

Applicant: David Wright ,  D. Parks

Inventor： David Wright ,  D. Parks

IPC: A61K38/54 ,  A61K38/10

CPC classification number: A61K38/10 ,  A61K38/204 ,  C07K5/0212 ,  C07K7/02

Abstract: This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO: 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the same activity as native IL-6 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage.

Abstract translation: 本发明提供了使用衍生自具有15至约40个氨基酸的白细胞介素-6（IL-6）的逆转换肽的治疗方法，并且包括相对于SEQ ID NO：1反向逆转的序列，即其中 所述肽包含序列D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D -Ala-D-Leu-D-Ala-D-Glu。 本发明的肽具有与天然IL-6相同的活性并具有神经营养活性。 由于它们的D-氨基酸连接，本发明的肽也不太容易在体内蛋白水解降解。

公开(公告)号：US20070054854A1

公开(公告)日：2007-03-08

申请号：US11501948

申请日：2006-08-09

Applicant: David Wright ,  D. Parks

Inventor： David Wright ,  D. Parks

IPC: A61K38/17 ,  A61K38/10

CPC classification number: C07K14/5403 ,  A61K38/10

Abstract: The invention provides methods of treatment using retro-inverso peptides derived from interleukin-3 (IL-3) having between 12 and about 40 amino acids and including the sequence that is retro-inverso with respect to SEQ ID NO: 1. These peptides of the invention have the same activity as native IL-3 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage.

Abstract translation: 本发明提供了使用衍生自具有12至约40个氨基酸的白细胞介素-3（IL-3）的逆转换肽并包括相对于SEQ ID NO：1的反向逆转的序列进行治疗的方法。 本发明具有与天然IL-3相同的活性，并且具有神经营养活性。 由于它们的D-氨基酸连接，本发明的肽也不太容易在体内蛋白水解降解。

公开(公告)号：US20070049520A1

公开(公告)日：2007-03-01

申请号：US11501975

申请日：2006-08-09

Applicant: David Wright ,  D. Parks

Inventor： David Wright ,  D. Parks

IPC: A61K38/16

CPC classification number: A61K38/10 ,  A61K38/16 ,  C07K5/0212 ,  C07K7/02 ,  C07K14/5415

Abstract: The invention provides methods of treatment using retro-inverso peptides derived from leukemia inhibitory factor (LIF) having between 18 and about 40 amino acids and including the sequence that is retro-inverso with respect to SEQ ID NO: 1. The peptides of the invention have the same activity as native LIF and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage.

Abstract translation: 本发明提供了使用衍生自具有18至约40个氨基酸的白血病抑制因子（LIF）的逆转换肽的治疗方法，并且包括相对于SEQ ID NO：1的反向逆转序列。本发明的肽 具有与天然LIF相同的活性，并具有神经营养活性。 由于它们的D-氨基酸连接，本发明的肽也不太容易在体内蛋白水解降解。

公开(公告)号：US20060287240A1

公开(公告)日：2006-12-21

申请号：US11508033

申请日：2006-08-21

Applicant: John O'Brien ,  D. Parks ,  Susan O'Brien

Inventor： John O'Brien ,  D. Parks ,  Susan O'Brien

IPC: A61K38/10

CPC classification number: A61K38/18 ,  A61K48/00 ,  C07K1/14 ,  Y02A50/466

Abstract: A method for stimulating prosaposin receptor activity in a cell by transfecting the cell with a DNA or RNA molecule encoding prosaposin or a prosaposin receptor agonist. The DNA or RNA molecule is administered either in vivo or used to transfect neural cells or neural stem cells ex vivo followed by reintroduction of the cells into an individual.